Ricardo Arechiga, PharmD candidate (2018)
Mr. Arechiga has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
It seems like an endless debate: When a patient does not respond to the first trial of an antidepressant, what should we do? Switch to something else? Augment with another agent? If the latter, how often should that augmenting agent be an atypical antipsychotic?
Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.